STOCK TITAN
  1. Home
  2. Sec-filings
  3. CADL
  4. [8-K] – Candel Therapeutics, Inc. (CADL) (CIK 0001841387)

[8-K] – Candel Therapeutics, Inc. (CADL) (CIK 0001841387)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Insights

Analyzing...

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CADL logo
Candel Therapeutics, Inc.

NASDAQ:CADL

CADL Rankings

#3720 Ranked by Market Cap
N/A Ranked by Dividends

CADL Latest News

Oct 14, 2025
Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer
Oct 14, 2025
Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.
Oct 14, 2025
Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine
Oct 3, 2025
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
Sep 29, 2025
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

CADL Latest SEC Filings

Aug 21, 2025
[8-K] Candel Therapeutics, Inc. Reports Material Event
Aug 14, 2025
[S-3] Candel Therapeutics, Inc. Shelf Registration Statement
Aug 14, 2025
[10-Q] Candel Therapeutics, Inc. Quarterly Earnings Report
Aug 14, 2025
[8-K] Candel Therapeutics, Inc. Reports Material Event
Jul 2, 2025
[Form 4] Candel Therapeutics, Inc. Insider Trading Activity

CADL Stock Data

355.17M
44.95M
16.76%
42.29%
13.24%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
NEEDHAM